Table 1.
Agent | Mechanism of Action | Type of Clinical Trial (number of subjects) |
Trial Status |
---|---|---|---|
Rituximab | CD20-directed ADCC | Open-label, prospective (n = 30) | Completed |
XmAb5871 | CD19-directed B cell inhibition | Open-label, prospective (n = 21) | Enrolling |
Abatacept | Co-stimulation blockade | Case report (n = 1) | - |
Elotuzumab | SLAMF7-directed ADCC | Unstudied | - |
AMG-557 | ICOS-directed Tfh inhibition | Unstudied | - |